

Avapritinib With Decitabine in Patients With SM-AHN

NCT06327685

Status	RECRUITING
Phase	Phase 1
Sponsor	H. Lee Moffitt Cancer Center and Research Institute
Enrollment	34 participants

Key Eligibility Criteria

Inclusion (11)

- Diagnosis of SM-AHN defined by World Health Organization 2022 criteria.
- ECOG 0-3
- Ability to understand and the willingness to sign a written informed consent.
- Ability to adhere to study visit schedule and other protocol requirements.
- Willing to receive blood products as deemed clinically necessary.

... and 6 more (see full listing online)

Exclusion (21)

- History of decitabine use with documented disease progression of AHN by 2006 IWG MDS response criteria while on decitabine.
- History of avapritinib use with documented progression of mastocytosis while on avapritinib per m-IWG-MRT-ECNM criteria.
- History of treatment with decitabine in combination with avapritinib.
- Use of azacitidine within 4 weeks of first dose of study drug.
- Diagnosis of AML defined as presence of ≥ 20% myeloblasts in the peripheral blood or bone marrow or presence of a myeloid sarcoma.

... and 16 more (see full listing online)

Locations (7 total)

Mayo Clinic - Arizona, Phoenix, Arizona, United States
Stanford University Medical Center, Palo Alto, California, United States
Moffitt Cancer Center, Tampa, Florida, United States

... and 4 more locations